These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18584943)

  • 1. Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Porru D
    Eur Urol; 2009 Mar; 55(3):720. PubMed ID: 18584943
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Rembratt A
    Eur Urol; 2009 Mar; 55(3):719. PubMed ID: 18584945
    [No Abstract]   [Full Text] [Related]  

  • 3. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Serati M; Salvatore S; Uccella S; Cardozo L; Bolis P
    Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
    Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Serati M; Salvatore S; Uccella S; Cromi A; Khullar V; Cardozo L; Bolis P
    Eur Urol; 2008 Oct; 54(4):911-5. PubMed ID: 18036728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
    Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
    BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 12. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.
    Ulahannan D; Wagg A
    Clin Interv Aging; 2009; 4():191-6. PubMed ID: 19503781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
    Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
    Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
    Chapple CR; Herschorn S; Abrams P; Wang JT; Brodsky M; Guan Z
    BJU Int; 2010 Nov; 106(9):1332-8. PubMed ID: 20497416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatrics: combining antimuscarinics shows promise for overactive bladder.
    Wyndaele JJ
    Nat Rev Urol; 2010 Feb; 7(2):66-8. PubMed ID: 20145662
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
    Streng T; Andersson KE; Hedlund P; Gratzke C; Baroni E; D'Ambrosio D; Benigni F
    BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2011 Apr; 185(4):1386. PubMed ID: 22098979
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
    Kaiho Y; Nishiguchi J; Kwon DD; Chancellor MB; Arai Y; Snyder PB; Yoshimura N
    BJU Int; 2008 Mar; 101(5):615-20. PubMed ID: 18070178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.